Jump to content

Impressive Results of Telcytaâ„¢ Chemotherapy a

Recommended Posts

Initial Therapy in Non-Small Cell Lung Cancer

http://patient.cancerconsultants.com/lu ... x?id=34588

Lung Cancer News

Impressive Results for Addition of Telcytaâ„¢ Chemotherapy as Initial Therapy in Non-Small Cell Lung Cancer

According to results recently presented at the Eleventh World Conference on Lung Cancer, the addition of Telcytaâ„¢ (TLK286) to standard chemotherapy provides impressive anti-cancer responses as initial therapy in advanced non-small cell lung cancer (NSCLC). These results were updated from presentations of the 2005 annual meeting of the American Society of Clinical Oncology (ASCO), held in May 2005.

Lung cancer is the leading cause of cancer-related deaths in the United States and Europe. NSCLC, which arises from the tissues of the lung, is the most common type of lung cancer. Under most circumstances, NSCLC is not curable. Current treatments include surgery and chemotherapy. Chemotherapy is often prescribed in the treatment of NSCLC and is designed to reduce or limit the growth of cancer cells. Stages IIB and IV NSCLC are advanced stages and refer to cancer that has spread from its site of origin to distant and/or several sites in the body.

Telcyta is a new drug that is considered a “prodrugâ€

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.